Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aditxt, Inc.

< Previous 1 2 Next >
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
From Aditxt, Inc.
Via GlobeNewswire
Tickers ADTX
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Issues Shareholder Update
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $20.0 Million Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Participate in the 2022 Virtual Growth Conference
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.